June 19th 2025
Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.
Navigating the Quality Landscape in Oncology: Pitfalls and Lessons Learned
Report Finds Hospitals Costlier for Cancer Care Than Community Practices